骨髓增生异常综合征临床研究

目的探讨沙利度胺、环孢素A及亚砷酸联合治疗骨髓增生异常综合征的临床疗效。方法将27例骨髓增生异常综合征患者随机分为对照组13例和治疗组14例。对照组予以雄激素、全反式维甲酸或小剂量化疗、干扰素等治疗6个月。治疗组采用沙利度胺、环孢素A及亚砷酸联合治疗方案，依患者耐受情况选用维持剂量并连用3—6个月。比较2组的临床疗效和不良反应。结果治疗组和对照组总有效率分别为78．57％（11／14）和46．15％（6／13）。2组总有效率比较，差异有统计学意义（P〈0．05）。治疗组中不良反应主要为剂量依赖性和可逆性，经对症处理后好转。大多数患者耐受良好，无治疗相关性死亡。结论沙利度胺、环孢素A及亚砷酸联合治疗骨髓增生异常综合征疗效确切，不良反府轻微．患者可耐受。

Influence of jinshuibao capsule on serum cystatin C and high sensitive C-reactive protein in chronic kidney disease patients

Objective To investigate thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome clinical efficacy.Methods 27 patients with myelodysplastic syndrome were randomly divided into control group 13 cases and 14 cases of treatment group.The control group to be male hormones,all-trans retinoic acid or a small-dose chemotherapy,interferon and other treatment for 6 months.The treatment group were treated with thalidomide,cyclosporine A,and arsenious acid combined treatment programs,according to patient tolerance,and used in conjunction to choose a maintenance dose of 3 to 6 months.Comparison of two groups of clinical efficacy and adverse reactions.Results The treatment group and control group,the total effective rate was 78.57% (11/14)and 46.15 % (6/13).The total effective rate,the difference was significant(P ＜ 0.05).The treatment group,adverse reactions and reversible dose-dependent manner mainly by symptomatic improvement after treatment.It was well tolerated in most patients,no treatment-related death.Conclusion Thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome accurate,adverse reactions are mild,the patient can be tolerated.